Business
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session
NAARDEN, The Netherlands and MIAMI, March 23, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a
About this update from Newamsterdam Pharma Company N.v.
[{"type":"text","content":"NAARDEN, The Netherlands and MIAMI, March 23, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the at the American College of Cardiology Annual Scientific Session (ACC.26), taking place on March 28-30 in New Orleans, Louisiana. Presentation details are as follows: Presentation Title: CETP Inhibition with Obicetrapib Preserved Kidney Function in Patients at High Cardiovascular Risk: Results from the BROADWAY Trial Session Title: 1069: Next-Generation Lipid Treatment OptionsDigital Poster Presentation Date and Time: Saturday, March 28, 2026, 3:30 - 3:37 PM CDT Presenter: John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer, NewAmsterdam PharmaLocation: Moderated Poster Theater 06, Posters, Hall E Presentation Title: Safety of Obicetrapib: An Integrated Pooled Phase III Safety Analysis Session Title: 1084: Evolving Non-Statin TherapiesDigital Poster Presentation Date and Time: Sunday, March 29, 2026, 10:18 - 10:25 AM CDT Presenter: Adam Nelson, Ph.D.Location: Moderated Poster Theater 05, Posters, Hall E Presentation Title: Cardiovascular Events in People with Normal Low-Density Lipoprotein Cholesterol Levels but Discordantly High Levels of Small/Medium LDL Particles Session Title: 1180: Linking Lipid Metrics to CVD RisksDigital Poster Presentation Date and Time: Monday, March 30, 2026, 11:00 - 11:07 AM CDT Presenter: Floriaan Schmidt, Ph.D.Location: Moderated Poster Theater 05, Posters, Hall E About ObicetrapibObicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company’s Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company’s Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect...